1

1

partnering to deliver Impact

1

Dr. Emily Vereker

Technology Transfer Case Manager,

Trinity College Dublin

Office of Corporate

Partnership & Knowledge

Exchange

2

22

ideas - innovation - entrepreneurship - knowledge transfer

2

290INVENTIONS

70LICENCES TO

INDUSTRY

38CAMPUS COMPANIES

TRINITY’S DEVELOPMENT PIPELINE (2008 – 2013)

3

33

a new perspective – industry

Technology Transfer PartnershipKnowledge Exchange

4

44

shift in business model

4

“….R&D is not a monolithic enterprise any longer, but more of a flexible function that finds the

innovation necessary to address each market’s need….”

- Christopher Bowe, US healthcare analyst for Informa’s Scrip Intelligence

5

55

industry challenges - academic enablers

patent cliffs

5

state funding

patent portfolio

R&D

infrastructure

CHALLENGES ENABLERS

graduates

business model shift for efficiency & economy

market shift, policy shift

managing shiftsin research focus

budgetary constraints

IP creation

early go-no-go decisions

R&D

Know how

& equipment

hospital /clinicalaffiliations

assays, processes methodologies

6

66

principles for engagement

open innovation - we want the IP to be practiced

not profit motivated - knowledge transfer for

socio-economic return

flexibility - open to a range of

mutually beneficial models for IP ownership

user-friendly - systems in place to

support and encourage engagement

practical - we want to do fair, quick deals

6

7

77

history of industrial partnerships

7

Global Innovative Companies

TCD collaborates with

14 of the top 20

Medical Device Companies

TCD collaborates with

8 of the top 10

ICT exporters in Ireland

TCD collaborates with

8 of the top 10

Trinity entered into

100 research agreements

with industry in 2012

8

88

top 30 collaborating companies 2008 - 2013

8

1 Intel 16 Amgen

2 Glaxo Smithkline 17 BASF

3 Applied Biosystems 18 Centocor

4 Boehringer Ingelheim 19 Dow Corning

5 Novartis 20 Dupont

6 Merck & Co. 21 Glantreo

7 Genetech 22 Brunker

8 Alere Technologies 23 Neurosearch

9 River Diagnostics 24 Henkel

10 Novo Nordisk 25 Alex Pharmaceuticals

11 Pfizer 26 Analysis Group

12 IBM 27 Astrazeneca

13 Clavis Pharma 28 Biofluidix

14 Norchip 29 European Central Bank

14 Vale Inco 30 Hewlett Packard

9

99

Trinity Biomedical Sciences Institute - Open Innovation

55PIs with labs

VITAL STATISTICS

520number of researchers

21,000m2

academic & teaching space

€10mvalue of equipment

3centers of research excellence

5schools

10

10

interdisciplinary competencies

TBSI immunology & biochemistry

pharmacy

chemistry

bioengineering

medicine

Cancer

medical devices

11

11

competencies

co

mp

ete

ncie

s

design

bio-engineering

neural engineering

electronics

Software

instruments

prototyping

target identification

medicinal chemistry

formulation

pathway/moa

animal model

transgenicso

utp

uts

stents

inhalers

bio-orthopaedics

Prosthetics

biomaterials

immuno therapeutics

cancer therapeutics

vaccines

adjuvants

new chemical entities

biomarkers

diagnostics

prognostics

efficiencies in care

12

1212

early drug discovery to validation capabilities

drug

candidate

-

in vivo

efficacy

preclinical development

in vitro efficacy

-

cellular disease assays

-

mechanism of action

-

pathways

cellular & molecular

pharmacology

library development

-

structure-based design optimisation

-

medicinal chemistry

medicinal chemistry

binding assays

-

high throughput screening

-

biochemical assays

lead discovery

structure determination

-

nmr

-

crystallog’y

-

mass spec

informatics & genomics

isolaton

-

purification

-

validation

target discovery

research target IDtarget

validat’nscreening

pre-clinical

Clinical Ph I, II, III

regulatory

13

13

case study - SIGMOID PHARMA

challenges

engagement type

Regular collaborations, availing of State funding; ‘Enterprise Partnership Scheme’, ‘Innovation Partnership Program’, contract research services and an FP7 partner

impact“..collaborating with the Lavelle group, the potential of SmPill® to enable oral vaccination has been proven…..allow Sigmoid to support its existing intellectual property portfolio, further characterise various vaccine formulations, complete pre-clinical development, and create new academic collaborative as well as commercialisation opportunities

critical enablers

Knowhow in the evaluation of innate and adaptive immuneresponses induced by mucosal adjuvants and in dissectingthe underlying mechanisms of adjuvanticity.

proprietary Single-multiple Pill (SmPill®) enables the combining of antigenic and adjuvant materials within an emulsion to permit the development of oral vaccines.

Requires assistance with design and evaluation of adjuvants,associated challenge models and infrastructure

14

1414

current industrial engagement

€700kOrla Hardiman

– Elan, Merck, Biogen, Novartis

€250kAnn Molloy – Axis Shield

~80industry collaborators

€500kMartin Caffrey

– B&I

€10mSFI – Industry funded

AMBER center

€350kDr.

– Company Y

15

1515

Dr. Emily Vereker

Technology Transfer Case Manager,

Trinity College Dublin

https://www.tcd.ie/biosciences/

http://www.tcd.ie/innovation/

emily.vereker@tcd.ie

(01) 896-4152

16

16

case study - ALKERMES, INC

challenge

engagement type

The Alkermes-Trinity research services engagement is adirect industry funded project. IP owned by Alkermes

impact“Leveraging existing state-of-the-art neurological techniques and scientific expertise advantageously strengthens our drug development profile and allows for rapid critical go/no-go decisions to be made”

critical enablers

Extensive technical expertise in the areas of learning andmemory, mechanisms of brain repair, drug action in the CNSand synaptic plasticity

unmet needs, debilitating diseases of the central nervous system (CNS), such as schizophrenia, addiction and depression.

• Requires assistance with progressing medicines morerapidly from discovery to development

• Alkermes Inc establishes new partnerships and leveragesestablished science as a key strategy

17

17

competencies

High throughput | virtual screening

Amir Chan

Martin Caffrey

Darren Fayne

modification

Mike Southern

Isabel Rozas

optimisation

M.Meegan

D.Zisterer

in vivo efficacy

target identification | isolation

L.O’Driscoll

M. Caffrey

D. Fayne

function determination

C.O’Farrelly

K. Mills

assay | pathway

K. Mills

L.O’Neill

C. Gardiner

in vivo efficacy

P.Fallon

E. Lavelle

feasibility

B.Murphy

D. Kelly

design verification

R. Reilly

Simmons

prototype

Prendergast

validation

devices

targets

biomarkers

drug

discovery

18

1818

early discovery to validation capabilities

identification

function determination

biochemical assays

in vivo validation

HTS virtual

screening

selection

modification

optimisation

in vivo efficacy

TARGETSBIOMARKERS

DRUG DISCOVERY

MEDICAL DEVICE

feasibility

design

verification

prototype

validation

19

1919

equipment & facilities

800MHz NMR with multiple probes

including cold probe

Tissue Culture Lab Confocal Microscopy

Fluorescent Activated Cells Sorter (FACS) Anatomy Teaching Lab Biochemistry Labs